UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts

UroGen Pharma Ltd. (NASDAQ:URGN) has been assigned an average rating of “Buy” from the six ratings firms that are presently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $43.70.

A number of research firms have weighed in on URGN. Oppenheimer reissued an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Friday, December 6th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of URGN. China Universal Asset Management Co. Ltd. boosted its stake in shares of UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares during the period. BNP Paribas Financial Markets lifted its position in UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares during the period. Intech Investment Management LLC purchased a new position in shares of UroGen Pharma in the 3rd quarter valued at approximately $155,000. Verition Fund Management LLC acquired a new position in shares of UroGen Pharma in the third quarter valued at approximately $168,000. Finally, SG Americas Securities LLC purchased a new stake in shares of UroGen Pharma during the third quarter worth approximately $179,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Stock Performance

Shares of URGN stock opened at $11.01 on Tuesday. The company has a market cap of $258.23 million, a P/E ratio of -3.50 and a beta of 1.09. The firm has a fifty day moving average price of $11.73 and a 200 day moving average price of $13.51. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 12 month low of $10.26 and a 12 month high of $20.70.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million for the quarter, compared to analyst estimates of $24.22 million. During the same period in the prior year, the company posted ($0.68) earnings per share. Sell-side analysts predict that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.